Onkure Therapeutics Inc
OKUR3.000USD
-0.100-3.23%
Handelsschluss 11/05, 16:00（ET）Kurse um 15 Minuten verzögert
40.59MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Onkure Therapeutics Inc Unternehmen
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KαH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3Kα and has multiple programs designed to enable targeting of this key oncogene.
Onkure Therapeutics Inc Informationen
BörsenkürzelOKUR
Name des UnternehmensOnkure Therapeutics Inc
IPO-datumApr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
Anzahl der mitarbeiter46
WertpapierartOrdinary Share
GeschäftsjahresendeApr 09
Addresse6707 Winchester Circle, Suite 400
StadtBOULDER
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl80301
Telefon17203072892
Websitehttps://onkuretherapeutics.com/
BörsenkürzelOKUR
IPO-datumApr 09, 2021
CEODr. Nicholas A. Saccomano, Ph.D.
Führungskräfte von Onkure Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
15.32K
+56.70%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dylan Hartley, Ph.D.
Dr. Dylan Hartley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ed T. Mathers ,
Ed T. Mathers ,
Independent Director
Independent Director
--
--
Ms. Valerie M. Jansen, M.D., Ph.D.
Ms. Valerie M. Jansen, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
15.32K
+56.70%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Acorn Capital Advisors, LLC
22.11%
Citadel Advisors LLC
8.48%
Shay Capital LLC
6.09%
The Vanguard Group, Inc.
5.50%
Cantor Fitzgerald, L.P
5.21%
Andere
52.60%
Aktionäre
Aktionäre
Anteil
Acorn Capital Advisors, LLC
22.11%
Citadel Advisors LLC
8.48%
Shay Capital LLC
6.09%
The Vanguard Group, Inc.
5.50%
Cantor Fitzgerald, L.P
5.21%
Andere
52.60%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
34.22%
Hedge Fund
24.32%
Investment Advisor/Hedge Fund
15.32%
Venture Capital
9.02%
Private Equity
3.83%
Individual Investor
1.73%
Research Firm
0.32%
Andere
11.25%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
177
11.18M
87.02%
-5.50M
2025Q2
186
12.83M
100.04%
-1.08M
2025Q1
187
12.71M
99.28%
-1.05M
2024Q4
190
12.64M
105.50%
+4.22M
2024Q3
172
2.79M
546.32%
-1.40M
2024Q2
171
3.11M
93.03%
-1.12M
2024Q1
161
3.05M
91.28%
-864.58K
2023Q4
152
2.81M
85.98%
-309.72K
2023Q3
128
3.01M
91.00%
-83.83K
2023Q2
119
2.90M
88.58%
+621.98K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Acorn Capital Advisors, LLC
2.84M
22.11%
--
--
Jun 30, 2025
Citadel Advisors LLC
1.09M
8.48%
+21.21K
+1.99%
Jun 30, 2025
Shay Capital LLC
782.05K
6.09%
-28.17K
-3.48%
Jun 30, 2025
The Vanguard Group, Inc.
706.73K
5.5%
--
--
Jun 30, 2025
Cantor Fitzgerald, L.P
669.54K
5.21%
+538.84K
+412.27%
Jun 30, 2025
Highbridge Capital Management, LLC
663.61K
5.17%
+224.81K
+51.23%
Jun 30, 2025
Vestal Point Capital, LP
635.00K
4.94%
--
--
Jun 30, 2025
StepStone Group LP
491.94K
3.83%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
478.55K
3.73%
--
--
Jun 30, 2025
BlackRock Financial Management, Inc.
463.59K
3.61%
--
--
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Nov 2
Aktualisiert: Sun, Nov 2
Name
Anteil
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
ALPS Medical Breakthroughs ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 ETF
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0%
iShares Russell 2000 ETF
Anteil0%
ProShares Ultra Nasdaq Biotechnology
Anteil0%
ALPS Medical Breakthroughs ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Global X Russell 2000 Covered Call ETF
Anteil0%
Invesco Nasdaq Biotechnology ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Datum
Art
Verhältnis
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
